Fig. 7
From: IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development
IGF2BP3 promotes the stability of HMGB1 mRNA and its expression in an m6A-dependent manner. A–C GSEA analysis reveals a positive correlation between IGF2BP3 mRNA levels and HALLMARKs of “INFLAMMATORY RESPONSE” and “ALLOGRAFT REJECTION” signatures in the TCGA BLCA, GSE31684, and E-MTAB-4321 datasets. D Comparison of HMGB1 mRNA levels between tumor and normal tissue in the TCGA BLCA dataset. E Heatmap showing the Spearman correlation coefficient between HMGB1 mRNA levels and IGF2BP3/METTL3 across 33 cancer types in the TCGA. F Scatterplot showing the mRNA expression correlation between IGF2BP3 and HMGB1 in the TCGA BLCA dataset. G, H RT-qPCR analysis of HMGB1 mRNA levels after IGF2BP3 overexpression in RT112/84 cells and IGF2BP3 knockdown in BFTC905 cells. I Western blot analysis of HMGB1, p65, and p-p65 protein levels after IGF2BP3 overexpression in RT112/84 cells and IGF2BP3 knockdown in BFTC905 cells. J Motif display of IGF2BP3 targeting consensus and the motif of m6A site. K RIP assays followed by RT-qPCR showing the binding of HMGB1 mRNA with IGF2BP3 protein. L, M RT-qPCR analysis of HMGB1 mRNA at different time points after treatment with actinomycin D (5 μg/ml) in RT112/84 cells following IGF2BP3 overexpression and in BFTC905 cells following IGF2BP3 knockdown. N Western blot analysis of HMGB1 protein levels after METTL3 overexpression in RT112/84 cells. O Scatterplot showing the mRNA expression correlation between METTL3 and HMGB1 in the TCGA BLCA dataset. P Correlation analysis of IGF2BP3 levels and tumor-infiltrating immune cells using the TIMER webtool. Q IGF2BP3 expression in different response groups; Kaplan–Meier overall survival (OS) estimates according to IGF2BP3 expression in bladder cancer patients treated with anti-PD-L1 antibody (atezolizumab) from “IMvigor210” dataset. R Kaplan–Meier OS and cancer-specific survival (CSS) estimates according to IGF2BP3 expression in the GSE19423 dataset of bladder cancer patients treated with Bacillus Calmette-Guérin (BCG) Immunotherapy. Kaplan–Meier survival curves with p-values derived from the log-rank test are shown. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05